Werkgroep Cardiologische centra Nederland

Dal-Outcomes II (Completed)

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
Medicine
dalcetrapib
Population
ASCVD
Phase
IIIB
Starting year
2011
More information
ClinicalTrials.gov

Director of Study

dr. E. Ronner (Cardioloog)
Delft, Reinier de Graaf Gasthuis

Dal-Outcomes II: News